Quantum Biopharma Files 6-K Report

Ticker: QNTM · Form: 6-K · Filed: Sep 10, 2025 · CIK: 1771885

Quantum Biopharma Ltd. 6-K Filing Summary
FieldDetail
CompanyQuantum Biopharma Ltd. (QNTM)
Form Type6-K
Filed DateSep 10, 2025
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, foreign-private-issuer, regulatory-update

TL;DR

Quantum Biopharma (fka FSD Pharma) filed a 6-K on 9/10/25, reporting from Toronto.

AI Summary

Quantum Biopharma Ltd. (formerly FSD Pharma Inc.) filed a Form 6-K on September 10, 2025, reporting for the month of September 2025. The company, incorporated in A6 and headquartered in Toronto, Canada, operates in the Pharmaceutical Preparations sector. This filing indicates they are submitting their report under Form 20-F.

Why It Matters

This filing is a routine report for foreign private issuers, providing an update on the company's activities and compliance with SEC regulations.

Risk Assessment

Risk Level: low — This is a standard foreign private issuer report (6-K) and does not contain specific financial or operational disclosures that would indicate immediate risk.

Key Players & Entities

  • Quantum Biopharma Ltd. (company) — Filer of the report
  • FSD Pharma Inc. (company) — Former name of Quantum Biopharma Ltd.
  • September 10, 2025 (date) — Filing date and reporting period
  • Toronto, Canada (location) — Company headquarters
  • 20-F (document) — Form under which annual reports are filed

FAQ

What is the primary purpose of a Form 6-K filing?

A Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the registrant makes or is required to make public in its home country, files or is required to file with a stock exchange, or distributes or is required to distribute to its security holders.

When was Quantum Biopharma Ltd. formerly known as?

Quantum Biopharma Ltd. was formerly known as FSD Pharma Inc., with a date of name change on March 27, 2019.

Where is Quantum Biopharma Ltd. headquartered?

Quantum Biopharma Ltd. is headquartered at 55 University Avenue, Suite 1003, Toronto, Ontario, M5J 2H7, Canada.

Under which SEC Act is this filing made?

This filing is made under the Securities Exchange Act of 1934.

Does Quantum Biopharma Ltd. file annual reports under Form 20-F or 40-F?

Quantum Biopharma Ltd. indicates it files annual reports under cover of Form 20-F.

Filing Stats: 151 words · 1 min read · ~1 pages · Grade level 11.4 · Accepted 2025-09-10 07:00:03

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Quantum BioPharma Ltd. (Registrant) Date: September 10, 2025 /s/ Donal Carroll Donal Carroll Chief Financial Officer EXHIBIT INDEX Exhibit Number Description 99.1 Press Release dated September 10, 2025

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.